Non-alcoholic fatty liver disease (NAFLD) is a public health problem, affecting up to a third of
the world's adult population. Several cohort studies have consistently documented that …

Abstract Type 2 diabetes (T2D) is a widely prevalent disease with substantial economic and
social impact for which multiple conventional and novel pharmacotherapies are currently …

Metabolic associated fatty liver disease (MAFLD) is the principal worldwide cause of liver
disease and affects nearly a quarter of the global population. The objective of this work was …

The obesity epidemic is closely associated with the rising prevalence and severity of
nonalcoholic fatty liver disease (NAFLD): obesity has been linked not only with simple …

A wealth of clinical and epidemiological evidence has linked obesity to a broad spectrum of
cardiovascular diseases (CVD) including coronary heart disease, heart failure …

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, with an
estimated rising prevalence, in concert with the epidemics of obesity and type 2 diabetes …

Non-alcoholic fatty liver disease (NAFLD) is to date the most common chronic liver disease
in clinical practice and, consequently, a major health problem worldwide. It affects …

Non-alcoholic fatty liver disease (NAFLD) is a quickly emerging global health problem
representing the most common chronic liver disease in the world. Atherosclerotic …

Nonalcoholic fatty liver disease (NAFLD) and diabetes mellitus are common diseases that
often coexist and might act synergistically to increase the risk of hepatic and extra-hepatic …

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease. Its
worldwide prevalence is rapidly increasing and is currently estimated at 24%. NAFLD is …